HighVista Strategies’s Neurocrine Biosciences NBIX Stock Holding History

HighVista Strategies’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-8,373	Closed	-$889K	–	119
2022 Q3	$889K	Buy	8,373 +4,606	+122%	+$467K	0.51%	47
2022 Q2	$367K	Buy	+3,767	New	+$348K	0.22%	83
2021 Q4	–	Sell	-13,205	Closed	-$1.27M	–	99
2021 Q3	$1.27M	Buy	13,205 +5,065	+62%	+$478K	0.84%	32
2021 Q2	$792K	Buy	+8,140	New	+$780K	0.56%	53

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HighVista Strategies's NBIX Position: Q4 2022 in Review

HighVista Strategies sold out of Neurocrine Biosciences (NBIX) in Q4 2022, closing a stake of 8,373 shares — an estimated $889K sold.

HighVista Strategies first reported a position in NBIX in Q2 2021 and held it in 4 quarters. The position peaked at $1.27M in Q3 2021. 529 funds tracked by Wall St. Rank hold NBIX as of Q4 2022.

HighVista Strategies reported no remaining Neurocrine Biosciences position as of Q4 2022 after selling out during the quarter.
HighVista Strategies sold 8,373 Neurocrine Biosciences shares in Q4 2022, an estimated $889K.
HighVista Strategies first reported a position in Neurocrine Biosciences in Q2 2021 and held it in 4 quarters.
HighVista Strategies's Neurocrine Biosciences position peaked at $1.27M in Q3 2021.
529 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2022.

Based on HighVista Strategies's 13F filing for Q4 2022, filed 14 Feb 2023.